ImmunoGen Announces Conference Call to Discuss Its First Quarter 2019 Operating Results
April 18 2019 - 3:30PM
Business Wire
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that the Company will host a conference call at
8:00 a.m. ET on Friday, May 3, 2019 to discuss its first quarter
operating results. Management will also provide a brief update on
the business.
Conference Call InformationTo access the live call by
phone, dial 323-994-2093; the conference ID is 8980567. The call
may also be accessed through the Investors and Media section of the
Company’s website, www.immunogen.com. Following the webcast, a
replay of the call will be available at the same location through
May 17, 2019.
ABOUT IMMUNOGENImmunoGen is developing the next
generation of antibody-drug conjugates (ADCs) to improve outcomes
for cancer patients. By generating targeted therapies with enhanced
anti-tumor activity and favorable tolerability profiles, we aim to
disrupt the progression of cancer and offer our patients more good
days. We call this our commitment to “target a better now.” The
Company has built a productive platform generating a broad pipeline
of ADCs targeting solid tumors and hematologic malignancies.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190418005025/en/
INVESTOR RELATIONS CONTACTSarah
Kiely781-895-0600sarah.kiely@immunogen.comMEDIA
CONTACTCourtney
O’Konek781-895-0600courtney.okonek@immunogen.comORFTI
ConsultingRobert
Stanislaro212-850-5657robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024